Is Sat Kartar overvalued or undervalued?

As of 26 August 2025, the valuation grade for Sat Kartar has moved from attractive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 26.13, an EV to EBITDA of 16.29, and a ROE of 19.07%.
In comparison to its peers, Sat Kartar's PE ratio is lower than Sun Pharma's 33.48 and Divi's Lab's 71.33, which are both considered expensive, while it is higher than Cipla's attractive valuation at 23.64. Despite the recent stock decline of 6.05% over the past week compared to a 1.08% drop in the Sensex, the company's financial performance remains solid, suggesting it is neither undervalued nor overvalued at this time.